Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):825–829. doi: 10.1038/bjc.1993.151

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.

J E Ferguson 1, D J Dodwell 1, A M Seymour 1, M A Richards 1, A Howell 1
PMCID: PMC1968370  PMID: 7682432

Abstract

Eighteen patients with advanced breast cancer were commenced on treatment with high dose doxorubicin (100 mg m-2) or doxorubicin (100 mg m-2) and cyclophosphamide (500 mg m-2) at 2 weekly intervals. Three cycles of treatment were planned. rG-CSF was given subcutaneously for 10 days, starting 24 h after each cycle of chemotherapy. Sixteen out of 18 patients responded (89%) of whom six (33%) achieved a complete remission. Twelve (67%) completed the three planned cycles, four (22%) received two cycles and two (11%) received one cycle only. The median time to progression was 5 1/2 months and the median survival was 18 1/2 months. Neutropenia occurred after 89% of courses and 65% of courses were accompanied by a significant (WHO grade III or IV) infection. The duration of neutropenia was short (mean 5.4 days) and mean time to absolute neutrophil count recovery (ANC > 1,000 x 10(6) litre) from the start of treatment was 11 days. Moderate to severe epithelial toxicity (WHO grade 3 or 4) accompanied 43% of courses and was dose limiting. Conclusion: High dose, dose intensive chemotherapy has an excellent initial therapeutic effect in advanced breast cancer but does not prolong duration of remission or overall survival beyond that of standard treatment. Although subcutaneous rG-CSF curtailed the expected duration of neutropenia substantially, the overall incidence of neutropenia and of infections requiring intravenous antibiotics was high. Furthermore, almost half of the courses were complicated by moderate to severe oral mucositis and/or mild to moderate palmar and plantar inflammation. The lack of survival benefit and excess toxicity seriously limits the wider application of this regime. It should not be used in place of standard dose palliative chemotherapy for metastatic breast cancer.

Full text

PDF
827

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bramwell V. H., Howell A., Anderson H., Rankin E. M. Intermediate dose single agent cyclophosphamide chemotherapy of advanced breast cancer. Clin Oncol. 1983 Sep;9(3):251–256. [PubMed] [Google Scholar]
  2. Bronchud M. H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989 Jul;60(1):121–125. doi: 10.1038/bjc.1989.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bronchud M. H., Potter M. R., Morgenstern G., Blasco M. J., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer. 1988 Jul;58(1):64–69. doi: 10.1038/bjc.1988.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bronchud M. H., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987 Dec;56(6):809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carmo-Pereira J., Costa F. O., Henriques E., Godinho F., Cantinho-Lopes M. G., Sales-Luis A., Rubens R. D. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 1987 Oct;56(4):471–473. doi: 10.1038/bjc.1987.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cullor J. S., Fairley N., Smith W. L., Wood S. L., Dellinger J. D., Inokuma M. S., Souza L. M. Hemogram changes in lactating dairy cows given human recombinant granulocyte colony stimulating factor (r-MethuG-CSF). Vet Pathol. 1990 Sep;27(5):311–316. doi: 10.1177/030098589002700502. [DOI] [PubMed] [Google Scholar]
  7. Frei E., 3rd, Antman K., Teicher B., Eder P., Schnipper L. Bone marrow autotransplantation for solid tumors--prospects. J Clin Oncol. 1989 Apr;7(4):515–526. doi: 10.1200/JCO.1989.7.4.515. [DOI] [PubMed] [Google Scholar]
  8. Groopman J. E., Molina J. M., Scadden D. T. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med. 1989 Nov 23;321(21):1449–1459. doi: 10.1056/NEJM198911233212106. [DOI] [PubMed] [Google Scholar]
  9. Gundersen S., Kvinnsland S., Klepp O., Kvaløy S., Lund E., Høst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1431–1434. doi: 10.1016/0277-5379(86)90075-1. [DOI] [PubMed] [Google Scholar]
  10. Gundersen S., Kvinnsland S., Klepp O., Lund E., Høst H. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer. 1990 Jan;26(1):45–48. doi: 10.1016/0277-5379(90)90255-r. [DOI] [PubMed] [Google Scholar]
  11. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Herrmann F., Schulz G., Lindemann A., Meyenburg W., Oster W., Krumwieh D., Mertelsmann R. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1989 Feb;7(2):159–167. doi: 10.1200/JCO.1989.7.2.159. [DOI] [PubMed] [Google Scholar]
  13. Jones R. B., Holland J. F., Bhardwaj S., Norton L., Wilfinger C., Strashun A. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol. 1987 Feb;5(2):172–177. doi: 10.1200/JCO.1987.5.2.172. [DOI] [PubMed] [Google Scholar]
  14. Jones R. B., Shpall E. J., Shogan J., Affronti M. L., Coniglio D., Hart L., Halperin E., Iglehart J. D., Moore J., Gockerman J. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 1;66(3):431–436. doi: 10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. Jönsson P. E., Malmberg M., Ericsson M., Ryden S. Weekly dose adriamycin as first line chemotherapy in advanced breast cancer. Anticancer Res. 1991 Mar-Apr;11(2):877–879. [PubMed] [Google Scholar]
  16. Morimoto A., Sakata Y., Watanabe T., Murakami N. Leucocytosis induced in rabbits by intravenous or central injection of granulocyte colony stimulating factor. J Physiol. 1990 Jul;426:117–126. doi: 10.1113/jphysiol.1990.sp018129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Richards M. A., Hopwood P., Ramirez A. J., Twelves C. J., Ferguson J., Gregory W. M., Swindell R., Scrivener W., Miller J., Howell A. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer. 1992;28A(6-7):1023–1028. doi: 10.1016/0959-8049(92)90447-a. [DOI] [PubMed] [Google Scholar]
  18. Souza L. M., Boone T. C., Gabrilove J., Lai P. H., Zsebo K. M., Murdock D. C., Chazin V. R., Bruszewski J., Lu H., Chen K. K. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986 Apr 4;232(4746):61–65. doi: 10.1126/science.2420009. [DOI] [PubMed] [Google Scholar]
  19. Steiner R., Stewart J. F., Cantwell B. M., Minton M. J., Knight R. K., Rubens R. D. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol. 1983 Nov;19(11):1553–1557. doi: 10.1016/0277-5379(83)90085-8. [DOI] [PubMed] [Google Scholar]
  20. Tajima T., Tokuda Y., Kubota M., Ohta M., Yokoyama S., Mitomi T., Nakamura Y., Watanabe K., Murakami M., Shinozuka T. [Role of autologous bone marrow transplantation in cancer chemotherapy]. Gan To Kagaku Ryoho. 1988 Nov;15(11):3018–3024. [PubMed] [Google Scholar]
  21. Tajima T., Tokuda Y., Ohta M., Okumura A., Norihisa Y., Kubota M., Noto T., Fujimoto T., Nakasaki H., Yokoyama S. [Autologous bone marrow transplantation as a measure against myelosuppression in cancer chemotherapy]. Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-1):1085–1093. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES